These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29364199)

  • 41. Extended anti-HER2 therapy in early breast cancer: longer beats shorter?
    Refae S; Pistilli B; Delaloge S
    Curr Opin Oncol; 2016 Nov; 28(6):469-475. PubMed ID: 27606697
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
    Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
    Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.
    Zhang B; Hurvitz S
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):520-30. PubMed ID: 27379947
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 45. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW; Liu MC; Yee D; Yau C; van 't Veer LJ; Symmans WF; Paoloni M; Perlmutter J; Hylton NM; Hogarth M; DeMichele A; Buxton MB; Chien AJ; Wallace AM; Boughey JC; Haddad TC; Chui SY; Kemmer KA; Kaplan HG; Isaacs C; Nanda R; Tripathy D; Albain KS; Edmiston KK; Elias AD; Northfelt DW; Pusztai L; Moulder SL; Lang JE; Viscusi RK; Euhus DM; Haley BB; Khan QJ; Wood WC; Melisko M; Schwab R; Helsten T; Lyandres J; Davis SE; Hirst GL; Sanil A; Esserman LJ; Berry DA;
    N Engl J Med; 2016 Jul; 375(1):11-22. PubMed ID: 27406346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 49. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.
    Jankowitz RC; Abraham J; Tan AR; Limentani SA; Tierno MB; Adamson LM; Buyse M; Wolmark N; Jacobs SA
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1205-12. PubMed ID: 24077916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
    Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
    Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neratinib and capecitabine for breast cancer brain metastases.
    Stirrups R
    Lancet Oncol; 2019 Apr; 20(4):e197. PubMed ID: 30910514
    [No Abstract]   [Full Text] [Related]  

  • 55. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.
    Jiang N; Song XW; Lin JJ; Wang ZY; Zhang BN; Li A; Yan RY; Yan HF; Fu XY; Zhou JL; Li CL; Cui Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1111-1119. PubMed ID: 28766379
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Updates on therapeutic approaches in HER2-positive disease.
    Dickler MN
    Clin Adv Hematol Oncol; 2010 Feb; 8(2):105-7. PubMed ID: 20386531
    [No Abstract]   [Full Text] [Related]  

  • 58. Neratinib Approved for HER2+ Breast Cancer.
    Cancer Discov; 2017 Sep; 7(9):OF1. PubMed ID: 28778899
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer.
    Ban M; Miše BP; Majić A; Dražić I; Vrdoljak E
    Future Oncol; 2018 Mar; 14(6):537-544. PubMed ID: 29164917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
    Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.